Skip to content
HLTH 5483

Special Authority Request, Rifaximin

HLTH 5483 comes up after a patient with cirrhosis has been admitted for hepatic encephalopathy and lactulose alone hasn't kept it controlled. PharmaCare accepts the request only from a gastroenterologist or an internal medicine specialist. Approval gives six months of coverage, with renewals on evidence of benefit.

At a glance

Checked October 2026

Form number
HLTH 5483
Issued by
BC PharmaCare, Ministry of Health
Where
British Columbia
Completed by
Gastroenterologist or internal medicine specialist
Format
Fillable PDF, or PharmaCare SA eForm
Language
English

What the HLTH 5483 is for

Rifaximin is a limited coverage drug in BC. This form asks PharmaCare to cover rifaximin 550 mg twice daily, taken with lactulose, to reduce the risk of overt hepatic encephalopathy coming back. PharmaCare decides on two facts: a hospitalization for encephalopathy associated with cirrhosis, and inadequate control despite the maximum tolerated dose of lactulose.

Coverage starts when the approval is entered in PharmaNet. It isn’t retroactive, so the patient pays for any fill before then.

Who completes it

A gastroenterologist or internal medicine specialist completes and signs the whole form. PharmaCare’s criteria list no practitioner exemptions, so the specialist submits a request even when they also manage the patient’s liver care long term. The patient has no part to fill in.

How to fill in the form

Section 1, Specialist information, and Section 2, Patient information

Enter the specialist’s name, mailing address, College ID and fax number. The fax number is marked critical for a timely response, and the PHN critical for processing. If PharmaCare has no fax or mailing address, it can’t send the decision back.

Section 3A, Initial coverage criteria (6 months)

Tick the confirmation that the prescriber is a gastroenterologist or internal medicine specialist, then the two clinical criteria: a hospitalization with hepatic encephalopathy associated with cirrhosis, and inadequate control on the maximum tolerated dose of lactulose. The discharge summary is the usual evidence for the first. For the second, the chart should show the lactulose dose reached and why it couldn’t go higher.

Section 3B, Exceptional renewal of coverage (1 year)

At renewal, describe the benefit and tolerability in concrete terms. The form asks you to compare the frequency of hospital admissions with the period before treatment, and to give the current lactulose regimen. A renewal that says only “doing well” gives PharmaCare nothing to compare.

Signature

Sign the consent statement confirming you’ve discussed with the patient why their information goes to PharmaCare. The signature is mandatory.

Common reasons it’s sent back

  • Submitted by a prescriber who isn’t a gastroenterologist or internist.
  • No hospitalization for hepatic encephalopathy, or one not linked to cirrhosis.
  • Lactulose not at maximum tolerated dose, or the dose not stated.
  • A renewal without admission frequency or the current lactulose regimen.
  • Missing fax number, mailing address or PHN.

Submitting and who pays

Submit through PharmaCare’s SA eForms, or fax the PDF to 1-800-609-4884 or mail it to PharmaCare, Box 9652 Stn Prov Govt, Victoria, BC V8W 9P4. PharmaCare’s Special Authority page currently gives about five weeks for regular requests and one business day for urgent ones, and says eForms are usually quicker.

PharmaCare doesn’t pay for the form. Approved coverage is subject to the patient’s plan rules, including any Fair PharmaCare deductible.

Get the official form

Download the current version from BC PharmaCare, Ministry of Health each time. Forms change without notice, and an old edition can be returned.

Official page ↗ PDF ↗

Medulla Forms

Fill HLTH 5483 from the visit and the chart.

Upload the fillable PDF to your practice's forms once. Medulla fills it from the visit and the chart open in your EMR, leaves blank anything the record doesn't support, and opens the form for your review. When it's done, save it to the patient's chart in one click.

Free 1-month trial. No credit card required.

Sources for this guide

Questions

Questions we hear a lot.

Can a family physician submit the rifaximin Special Authority?

No. PharmaCare requires the request to come from a gastroenterologist or an internal medicine specialist, and Section 1 of the form is headed for those specialists.

Is rifaximin covered for traveller's diarrhea or IBS?

Not under this form. HLTH 5483 covers only the reduction of overt hepatic encephalopathy recurrence in patients with cirrhosis who have been hospitalized for it.

How long does rifaximin coverage last?

Initial coverage lasts six months. An exceptional renewal, completed in Section 3B, lasts one year if you can show benefit and tolerability.

Does the patient need to stay on lactulose?

Yes. PharmaCare's criteria say rifaximin should be used with a maximally tolerated dose of lactulose, and the renewal asks for the current lactulose regimen.

Is patient information secure?

Yes. Medulla has a SOC 2 Type II report from an independent auditor, is HIPAA, PIPEDA, and PHIPA compliant, and is built and hosted in Canada, so patient data stays in the country and never gets pasted into consumer AI tools. Everything is encrypted in transit and at rest. See how we protect patient data.

More questions? Browse help.medulla.ca.